GlobeNewswire PharmaOriginal article
Medera Presents Late-Breaking Clinical Trial Data at ESC Congress 2026 Demonstrating Durable Improvement in HFpEF Cardiac Filling Pressures Following SRD-002 Gene Therapy
ConferencepositiveSRD-002Positive
AI Analysis
Summary
Medera presented late-breaking clinical trial data at ESC Congress 2026 showing SRD-002 gene therapy achieved durable improvement in HFpEF, with 80% of patients meeting the primary endpoint of normalized cardiac filling pressures at 12 months and approximately 30% reduction in peak exercise PCWP.
Clinical Trial Data
Primary Endpoint
Met
Patients
10
Outcome Details
80% of patients met prespecified threshold for normalization of cardiac filling pressures at 12 months; mean peak exercise PCWP reduced by approximately 30% at 12 months following single intracoronary dose
Importance:6/10
Sentiment:
0.85
gene therapyHFpEFcardiaclate-breaking dataESC Congress 2026
Read the original article
Published by GlobeNewswire Pharma on August 31, 2026 9:15 AM